Multivariable analyses of the association of M-CHIP with OS
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Cohort A: patients who had NGS testing before first treatment | |||
| No M-CHIP | Ref | Ref | |
| 1 M-CHIP mutation | 0.2 | 0.03-1.7 | .14 |
| ≥2 M-CHIP mutations | 4.7 | 1.4-15.9 | .01 |
| Age at time of NGS (each 1-y increase) | 1.1 | 1.06-1.1 | <.0001 |
| Cohort C: entire cohort | |||
| No M-CHIP | Ref | Ref | |
| 1 M-CHIP mutation | 0.9 | 0.5-1.6 | .65 |
| ≥2 M-CHIP mutations | 2.2 | 1.04-4.8 | .039 |
| Age at time of NGS (each 1-y increase) | 1.1 | 1.05-1.1 | <.0001 |
| History of treatment | 3.9 | 2.5-6.2 | <.0001 |
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Cohort A: patients who had NGS testing before first treatment | |||
| No M-CHIP | Ref | Ref | |
| 1 M-CHIP mutation | 0.2 | 0.03-1.7 | .14 |
| ≥2 M-CHIP mutations | 4.7 | 1.4-15.9 | .01 |
| Age at time of NGS (each 1-y increase) | 1.1 | 1.06-1.1 | <.0001 |
| Cohort C: entire cohort | |||
| No M-CHIP | Ref | Ref | |
| 1 M-CHIP mutation | 0.9 | 0.5-1.6 | .65 |
| ≥2 M-CHIP mutations | 2.2 | 1.04-4.8 | .039 |
| Age at time of NGS (each 1-y increase) | 1.1 | 1.05-1.1 | <.0001 |
| History of treatment | 3.9 | 2.5-6.2 | <.0001 |
Boldface indicates significant P value of <0.05.
F, female; HR, hazard ratio; M-CHIP, myeloid clonal hematopoeisis of indeterminate potential; NGS, next-generation sequencing; y, year.